Table 2.

Studies included in the clinical validation

Study	No. at CHMI	CHMI route	No. TBS+	No. biomarker+	No. treated for infection
MC-001	6	5 bites	6	6	6
MC-003*	29	5 bites	26*	25	26*
PfSPZ-CVac PYR	21	3200 DVI	6	15	15

CHMI = controlled human malaria infection; DVI = direct venous injection; PYR = pyrimethamine; TBS = thick blood smear.

* One MC-003 participant was treated on the basis of a mislabeled blood smear specimen and was excluded from this analysis as described in the text. The analysis herein includes n = 28 participants, including 25 who were blood smear–positive and 18S rRNA biomarker positive.